Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study.
Krzemień P, Kasperczyk S, Banach M, Kasperczyk A, Dobrakowski M, Tomasik T, Windak A, Mastej M, Catapano A, Ray KK, Mikhailidis DP, Toth PP, Howard G, Lip GYH, Tomaszewski M, Charchar FJ, Sattar N, Williams B, MacDonald TM, Penson PE, Jóźwiak JJ; LIPIDOGRAM2015 Investigators. Krzemień P, et al. Rheumatol Int. 2022 Feb;42(2):261-271. doi: 10.1007/s00296-021-05033-9. Epub 2021 Nov 10. Rheumatol Int. 2022. PMID: 34755204 Free PMC article.
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MA. Dytfeld D, et al. Among authors: kubicki t. Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059. Oncotarget. 2016. PMID: 27527861 Free PMC article.
Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A. Grzasko N, et al. Among authors: kubicki t. Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272684. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28092996
Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.
Łuczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybyłowicz-Chalecka A, Ratajczak B, Czerwińska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld D. Łuczak M, et al. Among authors: kubicki t. Pol Arch Intern Med. 2017 Jun 30;127(6):392-400. doi: 10.20452/pamw.4032. Epub 2017 May 25. Pol Arch Intern Med. 2017. PMID: 28546528 Free article.
High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.
Hus I, Mańko J, Jawniak D, Jurczyszyn A, Charliński G, Poniewierska-Jasak K, Usnarska-Zubkiewicz L, Sawicki M, Druzd-Sitek A, Świderska A, Kopińska A, Grząśko N, Raźny M, Wędłowska A, Perzyński A, Gałązka A, Dytfeld D, Kubicki T, Rodzaj M, Waszczuk-Gajda A, Drozd-Sokołowska J, Pogłódek B, Pasternak A, Długosz-Danecka M, Szymczyk A, Dmoszyńska A. Hus I, et al. Among authors: kubicki t. Oncol Lett. 2019 Dec;18(6):5811-5820. doi: 10.3892/ol.2019.10929. Epub 2019 Sep 27. Oncol Lett. 2019. PMID: 31788054 Free PMC article.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Jasielec JK, et al. Among authors: kubicki t. Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522. Blood. 2020. PMID: 32735641 Free PMC article. Clinical Trial.
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJ. Derman BA, et al. Among authors: kubicki t. Blood Cancer J. 2021 Feb 5;11(2):19. doi: 10.1038/s41408-021-00418-2. Blood Cancer J. 2021. PMID: 33563912 Free PMC article. Clinical Trial. No abstract available.
31 results